161 related articles for article (PubMed ID: 9718289)
1. The partial NMDA agonist D-cycloserine stimulates LH secretion in healthy volunteers.
van Berckel BN; Lipsch C; Gispen-de Wied C; Wynne HJ; Blankenstein MA; van Ree JM; Kahn RS
Psychopharmacology (Berl); 1998 Jul; 138(2):190-7. PubMed ID: 9718289
[TBL] [Abstract][Full Text] [Related]
2. Behavioral and neuroendocrine effects of the partial NMDA agonist D-cycloserine in healthy subjects.
van Berckel BN; Lipsch C; Timp S; Gispen-de Wied C; Wynne H; van Ree JM; Kahn RS
Neuropsychopharmacology; 1997 May; 16(5):317-24. PubMed ID: 9109102
[TBL] [Abstract][Full Text] [Related]
3. D-cycloserine increases positive symptoms in chronic schizophrenic patients when administered in addition to antipsychotics: a double-blind, parallel, placebo-controlled study.
van Berckel BN; Evenblij CN; van Loon BJ; Maas MF; van der Geld MA; Wynne HJ; van Ree JM; Kahn RS
Neuropsychopharmacology; 1999 Aug; 21(2):203-10. PubMed ID: 10432468
[TBL] [Abstract][Full Text] [Related]
4. The effects of low dose ketamine on sensory gating, neuroendocrine secretion and behavior in healthy human subjects.
van Berckel BN; Oranje B; van Ree JM; Verbaten MN; Kahn RS
Psychopharmacology (Berl); 1998 Jun; 137(3):271-81. PubMed ID: 9683005
[TBL] [Abstract][Full Text] [Related]
5. A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia.
Goff DC; Tsai G; Levitt J; Amico E; Manoach D; Schoenfeld DA; Hayden DL; McCarley R; Coyle JT
Arch Gen Psychiatry; 1999 Jan; 56(1):21-7. PubMed ID: 9892252
[TBL] [Abstract][Full Text] [Related]
6. d-cycloserine adjuvant therapy to conventional neuroleptic treatment in schizophrenia: an open-label study.
Cascella NG; Macciardi F; Cavallini C; Smeraldi E
J Neural Transm Gen Sect; 1994; 95(2):105-11. PubMed ID: 7865165
[TBL] [Abstract][Full Text] [Related]
7. Effects of D-cycloserine on negative symptoms in schizophrenia.
Duncan EJ; Szilagyi S; Schwartz MP; Bugarski-Kirola D; Kunzova A; Negi S; Stephanides M; Efferen TR; Angrist B; Peselow E; Corwin J; Gonzenbach S; Rotrosen JP
Schizophr Res; 2004 Dec; 71(2-3):239-48. PubMed ID: 15474895
[TBL] [Abstract][Full Text] [Related]
8. D-cycloserine in Schizophrenia: New Strategies for Improving Clinical Outcomes by Enhancing Plasticity.
Goff DC
Curr Neuropharmacol; 2017; 15(1):21-34. PubMed ID: 26915421
[TBL] [Abstract][Full Text] [Related]
9. Comparative effects of glycine and D-cycloserine on persistent negative symptoms in schizophrenia: a retrospective analysis.
Heresco-Levy U; Javitt DC
Schizophr Res; 2004 Feb; 66(2-3):89-96. PubMed ID: 15061240
[TBL] [Abstract][Full Text] [Related]
10. Selective increase in the extracellular D-serine contents by D-cycloserine in the rat medial frontal cortex.
Fujihira T; Kanematsu S; Umino A; Yamamoto N; Nishikawa T
Neurochem Int; 2007; 51(2-4):233-6. PubMed ID: 17662507
[TBL] [Abstract][Full Text] [Related]
11. D-cycloserine adjuvant therapy to molindone in the treatment of schizophrenia.
Rosse RB; Fay-McCarthy M; Kendrick K; Davis RE; Deutsch SI
Clin Neuropharmacol; 1996 Oct; 19(5):444-50. PubMed ID: 8889288
[TBL] [Abstract][Full Text] [Related]
12. A placebo-controlled crossover trial of D-cycloserine added to clozapine in patients with schizophrenia.
Goff DC; Henderson DC; Evins AE; Amico E
Biol Psychiatry; 1999 Feb; 45(4):512-4. PubMed ID: 10071726
[TBL] [Abstract][Full Text] [Related]
13. Absence of significant interactive effects of high-dose D-cycloserine and ethanol in healthy human subjects: preliminary insights into ethanol actions at the glycine B site of NMDA glutamate receptors.
Trevisan L; Petrakis IL; Pittman B; Gueorguieva R; D'Souza DC; Perry E; Limoncelli D; Krystal JH
Alcohol Clin Exp Res; 2008 Jan; 32(1):36-42. PubMed ID: 18028532
[TBL] [Abstract][Full Text] [Related]
14. Acute N-methyl-D,L-aspartate administration stimulates the luteinizing hormone releasing hormone pulse generator in the ovine fetus.
Bettendorf M; de Zegher F; Albers N; Hart CS; Kaplan SL; Grumbach MM
Horm Res; 1999; 51(1):25-30. PubMed ID: 10095166
[TBL] [Abstract][Full Text] [Related]
15. Anticonvulsant effects of the glycine/NMDA receptor ligands D-cycloserine and D-serine but not R-(+)-HA-966 in amygdala-kindled rats.
Löscher W; Wlaź P; Rundfeldt C; Baran H; Hönack D
Br J Pharmacol; 1994 May; 112(1):97-106. PubMed ID: 8032669
[TBL] [Abstract][Full Text] [Related]
16. Glycine-Binding Site Stimulants of NMDA Receptors Alleviate Extrapyramidal Motor Disorders by Activating the Nigrostriatal Dopaminergic Pathway.
Shimizu S; Sogabe S; Yanagisako R; Inada A; Yamanaka M; Iha HA; Ohno Y
Int J Mol Sci; 2017 Jul; 18(7):. PubMed ID: 28671605
[TBL] [Abstract][Full Text] [Related]
17. Differential effects of the N-methyl-D-aspartate and non-N-methyl-D-aspartate receptors of the excitatory amino acids system on LH and FSH secretion. Its effects on the hypothalamic luteinizing hormone releasing hormone during maturation in male rats.
Carbone S; Szwarcfarb B; Rondina D; Feleder C; Moguilevsky JA
Brain Res; 1996 Jan; 707(2):139-45. PubMed ID: 8919290
[TBL] [Abstract][Full Text] [Related]
18. The NMDA positive modulator D-cycloserine potentiates the neuroleptic activity of D1 and D2 dopamine receptor blockers in the rat.
Dall'Olio R; Gandolfi O
Psychopharmacology (Berl); 1993; 110(1-2):165-8. PubMed ID: 7870878
[TBL] [Abstract][Full Text] [Related]
19. The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments.
Buchanan RW; Javitt DC; Marder SR; Schooler NR; Gold JM; McMahon RP; Heresco-Levy U; Carpenter WT
Am J Psychiatry; 2007 Oct; 164(10):1593-602. PubMed ID: 17898352
[TBL] [Abstract][Full Text] [Related]
20. Actions of D-cycloserine at the N-methyl-D-aspartate-associated glycine receptor site in vivo.
Emmett MR; Mick SJ; Cler JA; Rao TS; Iyengar S; Wood PL
Neuropharmacology; 1991 Nov; 30(11):1167-71. PubMed ID: 1663594
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
